Lung Non-Small Cell Squamous Cancer - pembrolizumab + MK-1308 - PD-L1 expression

Association details:

Biomarker:	PD-L1 expression
Cancer:	Lung Non-Small Cell Squamous Cancer
Drug:	Keytruda (pembrolizumab) (PD1 inhibitor) + quavonlimab (MK-1308) (CTLA4 inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

Ann Oncol

Title:

Safety and Efficacy of Quavonlimab With Pembrolizumab in First-Line Advanced Non–Small Cell Lung Cancer

Published date:

12/14/2020

Excerpt:

Quavonlimab 25 mg Q6W plus pembrolizumab demonstrated similar efficacy...Efficacy was observed at all dose levels/schedules in patients with NSCLC. ORRs were 40.0% (95% CI, 24.9-56.7; arm A), 37.5% (95% CI, 22.7-54.2; arm B), 27.5% (95% CI, 14.6-43.9; arm C), and 35.7% (95% CI, 12.8-64.9; arm E)...Efficacy based on PD-L1 expression...